Pancragen

What is Pancragen?

Pancragen is a synthetic tetrapeptide consisting of lysine, glutamic acid, aspartic acid, and tryptophan (Lys-Glu-Asp-Trp, or KEDW), developed by Vladimir Khavinson as part of his bioregulator peptide system. It targets pancreatic tissue — both the insulin-producing beta cells and the enzyme-secreting acinar cells. With more than a dozen PubMed-indexed publications, including two small human studies and primate work, it is one of the better-characterized Khavinson bioregulators. A non-randomized study in elderly type 2 diabetes patients reported lower fasting glucose and insulin resistance, a small uncontrolled study in older adults with prediabetes reported lower glucose in about half of participants, and primate studies reported it outperformed glimepiride in normalizing insulin secretion.

What Pancragen Is Investigated For

Pancragen is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Trp) targeted at pancreatic tissue, studied for age-related type 2 diabetes, glucose tolerance improvement, insulin resistance reduction, and restoration of beta-cell function. Within the Khavinson catalog, it is one of the better-characterized entries: more than a dozen PubMed-indexed publications include two small human studies (an elderly type 2 diabetes cohort of 33 patients compared against untreated patients, and a 12-person uncontrolled study in older adults with prediabetes), rhesus monkey work showing normalized insulin and C-peptide responses, diabetic-rat studies, and cell-culture data on pancreatic transcription-factor upregulation (PDX1, NGN3, PAX6). The strongest signal is in the aged-primate insulin-normalization data, where Pancragen outperformed glimepiride. However, the clinical evidence remains small-sample Russian research, methodology details do not consistently meet Western trial standards, and independent replication outside the Khavinson program is essentially absent. Critically, any diabetic patient considering Pancragen must remain under endocrinology supervision — uncoordinated combination with insulin or sulfonylureas could produce hypoglycemia, and Pancragen is not a substitute for prescribed diabetes medication.

History & Discovery

Pancragen was developed by Vladimir Khavinson's bioregulator program at the St. Petersburg Institute of Bioregulation and Gerontology, in the same broader effort that produced the cortex, pineal, thymus, and cartilage tetrapeptides. The natural-extract counterpart in this lineage is Suprefort, a peptide complex from animal pancreatic tissue. Pancragen (Lys-Glu-Asp-Trp, KEDW) was synthesized as a chemically defined short-peptide counterpart, with the hypothesis that the tetrapeptide retains the pancreas-specific regulatory effects of the larger natural preparation in a more standardized form. The earliest indexed paper (Khavinson et al., 2005, PMID 16671579) describes the design logic: after finding a four-residue fragment common to insulin-stimulating polypeptides, the group synthesized KEDW as an analog of that fragment protected against gastrointestinal enzymes, and in alloxan-diabetic rats it partially restored insulin synthesis. With more than a dozen PubMed-indexed publications including two small human studies (a 33-patient elderly type-2-diabetes comparison and a 12-person prediabetes study) and rhesus monkey work, Pancragen is one of the better-characterized entries in the Khavinson catalog. Reported findings include improved glucose tolerance and reduced insulin resistance in elderly diabetic patients, normalized insulin and C-peptide responses in aged primates, and upregulation of pancreatic transcription factors (PDX1, NGN3, PAX6) in cell culture. As with the rest of the Khavinson program, however, this evidence is concentrated in a single research lineage, the human study is small, blinding and randomization standards do not consistently meet modern Western trial methodology, and independent Western replication of any of the core findings is essentially absent. The clinical claims for type-2-diabetes management substantially exceed what an independent reviewer would conclude from the available evidence.

How It Works

Pancragen is a four-amino-acid peptide that targets pancreatic cells. It is proposed to enter cell nuclei and activate genes responsible for insulin production and pancreatic cell maintenance. In aging, these genes can become less active — Pancragen may help restore their function, improving the pancreas's ability to regulate blood sugar.

Pancragen (Lys-Glu-Asp-Trp) is proposed to bind directly to DNA along the major groove, forming stable peptide-DNA complexes that regulate transcription of pancreatic genes. The source for that claim is a 2014 molecular-mechanics modelling study (Tarnovskaya et al., PMID 24770759), which concluded that major-groove binding is sequence-specific and proposed GGCAG as the putative binding site — a computer simulation, not a laboratory measurement. A 2015 follow-up (Ashapkin et al., PMID 25761685) linked age- and peptide-induced changes in PDX1, PAX6, and NGN3 expression in pancreatic cells to changes in promoter methylation, offering an epigenetic route to the same effect. It increases expression of key pancreatic transcription factors including PDX1, NGN3, PAX6, FOXA2, NKX2-2, NKX6.1, and PAX4 — fundamental regulators of beta-cell development and function. In aging pancreatic cultures, it enhances expression of MMP2, MMP9, serotonin, and CD79alpha while reducing apoptosis markers, indicating both functional stimulation and cell survival effects. It also stimulates differentiation factors in acinar and islet cells, with effects more pronounced in aged tissue. In diabetic rat models, oral administration produced hypoglycemic effects while injection normalized endothelial adhesion in mesenteric capillaries, suggesting both metabolic and vascular protective mechanisms.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Pancragen:

• 01Independent replication outside the Khavinson research program — the human study and primate findings have not been reproduced by Western laboratories under modern trial-methodology standards.
• 02Larger blinded randomized controlled trials in humans for type-2-diabetes management — the two existing human studies (a 33-patient non-randomized comparison and a 12-person uncontrolled prediabetes study) are too small to support clinical conclusions, and neither reports randomization, blinding, or group sizes clearly.
• 03Independent laboratory validation of the DNA-binding mechanism — the major-groove / GGCAG binding site comes from a computer modelling study (PMID 24770759), not from binding measured in a laboratory.
• 04Pharmacokinetics in humans — absorption (particularly oral and sublingual bioavailability of the intact tetrapeptide), distribution to pancreatic tissue, and clearance have not been characterized.
• 05Mechanism specificity — direct DNA interaction by a tetrapeptide and the resulting pancreas-specific transcription-factor activation claim has not been independently validated.
• 06Long-term safety with cumulative repeated courses, including any effects on pancreatic-cell proliferation that could become problematic with chronic use or in subclinical malignancy.
• 07Combination safety and efficacy with standard diabetes medications — Pancragen has not been formally studied as adjunctive therapy alongside insulin, sulfonylureas, metformin, or GLP-1 agonists.

Forms & Administration

Pancragen is available in capsule, sublingual, and injectable formats. In primate studies, intramuscular injection of 50 mcg/day for 10 days was used. Capsule protocols typically involve 1-2 capsules daily for 10-30 days. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Claims for type-2-diabetes management, beta-cell restoration, and metabolic improvement exceed what the evidence base — two small human studies and animal data from one research network — can independently support. Not FDA-approved. Russian protocols come from a single-lab tradition not validated by Western-standard trials. Pancragen is not a substitute for prescribed diabetes medication. Research-chemical injectable supply is not authorized for human use.

Timeline of Effects

Common Questions

Who Pancragen Is NOT For

Drug & Supplement Interactions

Documented clinical drug interactions for Pancragen are essentially absent; no formal interaction studies meeting Western standards have been published. The most clinically meaningful theoretical concern is with anti-diabetic medication: insulin, sulfonylureas (glyburide, glipizide, glimepiride), and meglitinides could be potentiated if Pancragen contributes to glucose lowering, raising hypoglycemia risk in uncoordinated combination. The published primate study positioned Pancragen as mechanistically distinct from glimepiride (acting on beta-cell function rather than on potassium channels), but functional combination has not been formally studied. Concurrent use with metformin, GLP-1 agonists, SGLT2 inhibitors, or DPP-4 inhibitors has not been studied either. Combination with other Khavinson bioregulators is common in forum culture but unstudied. Patients on any diabetes medication, hormonal therapy, or oncology-related treatment should disclose Pancragen use to their prescribing clinician.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions